| Title: |
Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women. |
| Authors: |
Chen, Beatrice A, Zhang, Jingyang, Gundacker, Holly M, Hendrix, Craig W, Hoesley, Craig J, Salata, Robert A, Dezzutti, Charlene S, van der Straten, Ariane, Hall, Wayne B, Jacobson, Cindy E, Johnson, Sherri, McGowan, Ian, Nel, Annalene M, Soto-Torres, Lydia, Marzinke, Mark A |
| Source: |
Clinical Infectious Diseases; Apr2019, Vol. 68 Issue 7, p1144-1151, 8p |
| Subject Terms: |
WOMEN'S health, AGE distribution, ANALYSIS of variance, CERVICAL caps, DRUGS, DRUG side effects, FLUIDS, HIV infections, PREVENTIVE medicine, PATIENT compliance, PATIENT safety, SELF-evaluation, REPRODUCTIVE health, RANDOMIZED controlled trials, TREATMENT effectiveness, REPEATED measures design, POSTMENOPAUSE, REVERSE transcriptase inhibitors |
| Geographic Terms: |
UNITED States |
| Abstract: |
Background Postmenopausal women have unique sociobiological human immunodeficiency virus (HIV) risks. We evaluated the safety, pharmacokinetics, and acceptability of a microbicide dapivirine (DPV) vaginal ring (VR) versus placebo in postmenopausal women. Methods We enrolled 96 HIV-negative postmenopausal US women in a phase 2a double-blind, randomized (3:1) trial of monthly VRs containing 25 mg DPV or placebo used continuously for 12 weeks. We assessed safety by adverse events (AEs). DPV concentrations were quantified in plasma and vaginal fluid. Steady-state concentrations were analyzed at 4, 8, and 12 weeks using repeated measures ANOVA. We assessed acceptability by self-report. Results We found no differences in the proportion of women with related grade 2 or higher reproductive system AEs (DPV: 6/72 (8%), placebo: 3/24 (13%), P =.68) or grade 3 or higher AEs (DPV: 4/72 (6%), placebo: 0/24 (0%), P =.57). In the DPV arm, 2/72 (3%) declined to resume product use due to AEs. Median DPV concentrations in plasma (262.0 pg/mL at week 12) and vaginal fluid (40.6 ng/mg at week 12) were constant over 12 weeks and exceeded the in vitro 50% effective concentration by 5000-fold in vaginal fluid by week 4. VR acceptability was high; 84/93 (90%) "very much liked or liked" the VR. Conclusions DPV VRs were safe, well tolerated, and acceptable in postmenopausal women. Plasma concentrations were comparable to published data on DPV use in reproductive-age women (median plasma concentration: 264 pg/mL). Given the reassuring safety and pharmacokinetic data, the DPV VR is promising for preexposure prophylaxis in postmenopausal women. Clinical Trials Registration NCT02010593. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
